Founded based on the results of regenerative medicine research covering spinal cord injury, etc. and drug discovery (iPS cell based drug discovery) using disease-specific iPS cell based drug discovery technology, carried out over many years by the research group of Professor and Chair Hideyuki Okano at the Department of Physiology and Professor and Chair Masaya Nakamura at the Department of Orthopedic Surgery, both at Keio University School of Medicine. K Pharma is the world leader in this field, having been the first in the world to confirm the effectiveness of iPS cell based drug discovery. We are developing both the regenerative medicine business targeting spinal cord injury and cerebral infarction using iPS cells and the iPS cell based drug discovery business including amyotrophic lateral sclerosis (ALS), and worldwide development in the resolution of unmet medical needs can be expected.